Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | 2.0 |
Min SIP Amount | ₹100 | ₹1000 |
Expense Ratio | 0.77 | 1.78 |
NAV | ₹18.61 | ₹211.36 |
Fund Started | 06 Apr 2023 | 12 Feb 2001 |
Fund Size | ₹465.12 Cr | ₹8351.55 Cr |
Exit Load | - | Exit load of 0.50% if redeemed within 3 months. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -0.28% | -8.22% |
3 Year | - | 14.06% |
5 Year | - | 22.88% |
1 Year
3 Year
5 Year
Equity | 99.70% | 94.66% |
Cash | 0.30% | 2.05% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
BSE Ltd. | 3.08% |
Hero Motocorp Ltd. | 2.08% |
Persistent Systems Ltd. | 1.77% |
Suzlon Energy Ltd. | 1.70% |
Coforge Ltd. | 1.66% |
The Federal Bank Ltd. | 1.65% |
PB Fintech Ltd. | 1.60% |
Cummins India Ltd. | 1.57% |
Dixon Technologies (India) Ltd. | 1.56% |
Indusind Bank Ltd. | 1.47% |
Name | Assets |
|---|---|
Nifty MidCap Select Index | 15.25% |
Aurobindo Pharma Ltd. | 8.77% |
Tata Communications Ltd. | 8.62% |
IRB Infrastructure Developers Ltd. | 6.57% |
Premier Energies Ltd. | 6.47% |
GMR Airports Ltd. | 5.89% |
Reliance Industries Ltd. | 5.79% |
Lloyds Metals & Energy Ltd. | 5.36% |
Linde India Ltd. | 3.42% |
Anthem Biosciences Ltd. | 2.43% |
Name | Nirman S. Morakhia | Ankit A Pande |
Start Date | 07 Mar 2025 | 11 May 2020 |
Name
Start Date
Description | The scheme seeks to generate returns that are commensurate (before fees and expenses) with the performance of the NIFTY Midcap 150 Index, subject to tracking error. | The scheme aims at providing long term capital appreciation and generating income with a diversified portfolio of Mid Cap companies. |
Launch Date | 06 Apr 2023 | 12 Feb 2001 |
Description
Launch Date